Advanced Bladder Cancer VL

Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde

Details
Ashish Kamat hosts Guru Sonpavde to discuss key findings from the GU ASCO symposium. Dr. Sonpavde reviews a range of groundbreaking studies, emphasizing the potential of systemic therapy for metastatic bladder cancer. Noteworthy trials include TROPHY-U-01, which shows a 34% response rate combining sacituzumab govitecan with pembrolizumab, and a study on neoadjuvant enfortumab vedotin revealing a 3...

Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas

Details
Alicia Morgans talks with Petros Grivas about the TROPHY-U-01 study, which evaluates the efficacy of combining Sacituzumab govitecan (SG) with anti-PD-1 pembrolizumab in patients with platinum-refractory advanced urothelial cancer. Dr. Grivas elaborates on the study's rationale, citing SG's FDA approval based on a 27% response rate and tolerability. The study aims to explore the potential benefits...

Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis

Details
Dimitrios Makrakis joins Alicia Morgans and Petros Grivas in a discussion on a BJU International publication titled The Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer looking at a data set trying to understand the important potential interaction between exposure to checkpoint inhibitors and local therapy for patients at the time of diagnosis ass...

Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack

Details
Alicia Morgans is joined by Elizabeth Plimack to discuss the importance of the Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program. BCAN is the Bladder Cancer Advocacy Network which started as a small group of urology-based advocates and has grown to "the" organization for bladder cancer advocacy. The Young Investigator Award program strives to grow the science in bladder can...

Biomarkers and Next Generation Sequencing in Advanced Bladder Cancer - Noah Hahn

Details
In this 2021 LUGPA presentation, Noah Hahn presents " Biomarkers and Next-Generation Sequencing in Advanced Bladder Cancer Patients" . Dr. Hahn discusses the differences in prognostic biomarkers and predictive biomarkers before discussing PD-L1 on the immunohistochemistry side, sequencing biomarkers, tumor mutational burden, and microsatellite instability or mismatch repair deficient tumors. Biogr...

Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky

Details
In this conversation with Alicia Morgans, Matthew Galsky highlights an exploratory analysis within the IMvigor130 randomized phase III study of patients with metastatic urothelial cancer who were treatment-naive. IMvigor130 was asking two separate questions, should we combine platinum-based chemotherapy with atezolizumab versus giving platinum-based chemotherapy alone, and should we give immune ch...

Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo

Details
In this UroToday discussion between Petros Grivas, MD, PhD, Guru Sonpavde, MD, and Maria Carlo, MD, the trio discuss recent publications on germline testing and genetic profiling. The conversation kicks off with a background on Dr. Carlo’s recent work concerning genetic testing for urothelial and bladder cancer patients. The conversation shifts to hear from Dr. Sonpavde about his recent work in lo...

Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary...

Details
In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...

Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt

Details
In this UroToday discussion between Alicia Morgans and Samuel Funt, they discuss Samuel Funt’s recent phase 2 trial evaluating the use of atezolizumab, with gemcitabine and cisplatin, as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). The conversation begins with background on the study, beginning with Dr. Funt’s description of neoadjuvant cisplatin-based chemotherapy as the standar...

Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander

Details
In this discussion, Alicia Morgans and Terence Friedlander discuss updates from the EV-103 study. The EV-103 study is a phase one/two clinical trial that looked at the combination of enfortumab vedotin and pembrolizumab in, previously treated, patients with cisplatin-ineligible, metastatic urothelial cancer. Historically, cisplatin-ineligible metastatic urothelial cancer patients have had a very p...